Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OT-A201 is a first-in-class bispecific antibody, which is currently being evalauted in phase 1 clinical trials for the treatment of hematological malignancy & solid tumor.
Lead Product(s): OT-A201
Therapeutic Area: Oncology Product Name: OT-A201
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biomunex Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024